CYLD sirna

CYLD siRNA (Rat)

Cat. Num. AAA8217075

• Gene Names: Cyld; Rp1; Rp1h; LRRGT00003
• Reactivity: Rat
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CYLD; CYLD siRNA (Rat); CYLD1; Ubiquitin carboxyl-terminal hydrolase CYLD; Deubiquitinating enzyme CYLD; Ubiquitin thioesterase CYLD; Ubiquitin-specific-processing protease CYLD; CYLD sirna

• Host: Synthetic
• Reactivity: Rat
• Specificity: CYLD siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 953

• Applicable Applications for CYLD sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat CYLD gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CYLD sirna

siRNA to inhibit CYLD expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 62821831
• NCBI GeneID: 312937
• NCBI Accession #: NP_001017380.1
• NCBI GenBank Nucleotide #: NM_001017380.1
• UniProt Accession #: Q66H62
• Molecular Weight: 106,713 Da
• NCBI Official Full Name: ubiquitin carboxyl-terminal hydrolase CYLD
• NCBI Official Synonym Full Names: cylindromatosis (turban tumor syndrome)
• NCBI Official Symbol: Cyld
• NCBI Official Synonym Symbols: Rp1; Rp1h; LRRGT00003
• NCBI Protein Information: ubiquitin carboxyl-terminal hydrolase CYLD
• UniProt Protein Name: Ubiquitin carboxyl-terminal hydrolase CYLD
• Protein Family: Ubiquitin carboxyl-terminal hydrolase
• UniProt Gene Name: Cyld
• UniProt Synonym Gene Names: Cyld1
• UniProt Entry Name: CYLD_RAT

Uniprot Description

CYLD: Protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis. Interacts (via CAP-Gly domain) with IKBKG/NEMO (via proline-rich C-terminal region). Interacts with TRAF2 and TRIP. Interacts with PLK1, DVL1, DVL3, MAVS, TBK1, IKKE and DDX58. Interacts (via CAP-Gly domain) with microtubules. Interacts with HDAC6 and BCL3. Interacts with SQSTM1 and MAP3K7. Identified in a complex with TRAF6 and SQSTM1. Detected in fetal brain, testis, and skeletal muscle, and at a lower level in adult brain, leukocytes, liver, heart, kidney, spleen, ovary and lung. Isoform 2 is found in all tissues except kidney. Inhibited by phosphorylation at serine residues. Belongs to the peptidase C67 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Ubiquitin-specific protease; Protease; Ubiquitin conjugating system; Tumor suppressor; EC 3.4.19.12

Cellular Component: nucleoplasm; centrosome; extrinsic to internal side of plasma membrane; perinuclear region of cytoplasm; cytoplasmic microtubule; plasma membrane; spindle; midbody; nucleus; cytosol

Molecular Function: structural constituent of ribosome; zinc ion binding; ubiquitin-specific protease activity; protein kinase binding

Biological Process: ubiquitin-dependent protein catabolic process; Wnt receptor signaling pathway; protein deubiquitination; inhibition of NF-kappaB transcription factor; regulation of mitotic cell cycle; negative regulation of NF-kappaB import into nucleus; negative regulation of T cell differentiation